Eli Lilly Reports $197.99B Q1 Revenue, Raises 2026 Guidance on Tirzepatide Strength

According to Eli Lilly’s Q1 2026 earnings report released on April 30, the company reported first-quarter revenue of $197.99 billion, up 56% year-over-year, with net income of $73.96 billion, surging 168% compared to the prior year. Tirzepatide, the company’s GLP-1/GIP drug, contributed $128.22 billion to Q1 revenue, accounting for 64% of total sales. Mounjaro, the diabetes version, generated $86.62 billion (up 125%), while Zepbound, the weight-loss variant, brought in $41.6 billion (up 80%).

Based on this performance, Eli Lilly raised its full-year 2026 revenue guidance by $2 billion to $820–850 billion and increased non-GAAP earnings per share guidance to $35.50–$37.00. The stock rose over 8% in premarket trading on the announcement.